Please type a plus sign (+) inside this box -

PTO/SB/05 (03-01)
Approved for use through 10/31/2002 OMB 0651-0032
U.S Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

UTILITY PATENT APPLICATION **TRANSMITTAL**

NEX 01/C8 Attorney Docket No. Gold et al. First Inventor Nucleic Acid Ligands

(Only for new nonprovisional applications under 37 CFR 1.53(b))

EL652339952US Express Mail Label No.

	TION ELEMENTS	ADDRESS 7				
	perning utility patent application conte		Washington, DC 20231			
	orm (e.g., PTO/SB/17) duplicate for fee processing)		or CD-R in duplicate, large table or			
2. Applicant claims s See 37 CFR 1.27.		8. Nucleotide and/	Computer Program (Appendix) 8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)			
3. X Specification (preferred arrangement	[Total Pages 213]	` 	Computer Bondahlo Form (CBE)			
- Descriptive title			Sequence Listing on:			
	e to Related Applications arding Fed sponsored R & D		CD-ROM or CD-R (2 copies); or			
	equence listing, a table,		paper			
or a computer p - Background of	rogram listing appendix		nents verifying identity of above copies			
- Brief Summary	of the Invention	<u> </u>	ANYING APPLICATION PARTS			
- Brief Descriptio - Detailed Descri	n of the Drawings (if filed)		nent Papers (cover sheet & document(s))			
- Claim(s)		37 CFF	R 3.73(b) Statement Power of			
- Abstract of the			here is an assignee) Attorney			
4. X Drawing(s) (35 U	S.C. 113) [Total Sheets 34	٠ بــا ١	Translation Document (if applicable)			
5. Oath or Declaration	[Total Pages		ent (IDS)/PTO-1449 Citations			
	uted (original or copy)		nary Amendment			
b. X Copy from a	prior application (37 CFR 1.63 (d)) tion/divisional with Box 18 completed)	(Should	14. X Return Receipt Postcard (MPEP 503) (Should be specifically itemized)			
	ION OF INVENTOR(S)	15. Certifie	15. Certified Copy of Priority Document(s) (if foreign priority is claimed)			
	tement attached deleting inventor(s) he prior application, see 37 CFR	16 Nonpul	Nonpublication Request under 35 U.S.C. 122			
1.63(d)(2)	and 1.33(b)	(b)(2)(E	(b)(2)(B)(i). Applicant must attach form PTO/SB/35			
6. X Application Data	Sheet. See 37 CFR 1.76	17. X Other:	quivalent. Request to Transfer PreviouslyFiled.Sequence.Information			
18. If a CONTINUING APPLI	CATION, check appropriate box, and	pply the requisite informa	ation below and in a preliminary amendment,			
or in an Application Data She						
X Continuation	Divisional Continuation-in-part (i		of prior application No			
Prior application information For CONTINUATION OR DIVISI			which an oath or declaration is supplied under			
Box 5b, is considered a part of	the disclosure of the accompanying co	nuation or divisional appli	cation and is hereby incorporated by reference.			
The incorporation <u>can only</u> be relied upon when a portion has been inadvertently omitted from the submitted application parts. 19. CORRESPONDENCE ADDRESS						
OF OTA						
Costomer Walliber of Bar Co	ode Label Linsert Customer No. or After	bar code label here)				
Name						
Address						
City		State	Zip Code			
Country		elephone	Fax			
Name (Print/Type)	Margaret M. Wall	Registration No	o. (Attorney/Agent) 33,462			
11 12 12 12 12 12 12 12 12 12 12 12 12 1			Date Oct 18, 2001			
Signature Date UCL (8, 2001)						

the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231 DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231



APPENDING BEAUTIFE WILLIAM OF A SELECTION OF

Express Mail No. EL652339952US

Approved for use through 10/31/2002 OMB 0651-0032

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number

FEE TRANSMITTAL for FY 2001

Patent fees are subject to annual revision

TOTAL AMOUNT OF PAYMENT

(\$)	7	8	በ	U	ſ
(Ψ)	1	O	υ	v	١

Complete if Known		
Application Number		
Filing Date	October 18, 2001	-
First Named Inventor	Gold et al.	
Examiner Name		
Group Art Unit		
Attorney Docket No.	NEX 01/C8	

METHOD OF PAYMENT	FEE CALCULATION (continued)				
1. X The Commissioner is hereby authorized to charge indicated fees and readily any overnayments to	3. ADDITIONAL FEES				
Denosit	Large Small				
Account Number 22-0277 * any deficiency	Entity Entity Fee Fee Fee Fee Fee Description F	Fee Paid			
Denosit	Fee Fee Fee Fee Fee Description F	ree Faiu			
Account Nexstar Pharmaceuticals, Inc.	105 130 205 65 Surcharge - late filing fee or oath				
Charge Any Additional Fee Required Under 37 CFR 1 16 and 1.17	127 50 227 25 Surcharge - late provisional filing fee or cover sheet				
Applicant claims small entity status.	139 130 139 130 Non-English specification				
See 37 CFR 1 27	147 2,520 147 2,520 For filing a request for ex parte reexamination				
2. Payment Enclosed:	112 920* 112 920* Requesting publication of SIR prior to Examiner action				
Check Credit card Order Other	113 1,840* 113 1,840* Requesting publication of SIR after				
FEE CALCULATION	Examiner action				
1. BASIC FILING FEE	115 110 215 55 Extension for reply within first month				
Large Entity Small Entity	116 390 216 195 Extension for reply within second month				
Fee Fee Fee Fee Description Code (\$) Code (\$) Fee Paid	117 890 217 445 Extension for reply within third month				
0000 (4)	118 1,390 218 695 Extension for reply within fourth month				
101 710 201 355 Utility filing fee 740.00	128 1,890 228 945 Extension for reply within fifth month				
107 490 207 245 Plant filing fee	119 310 219 155 Notice of Appeal				
108 710 208 355 Reissue filing fee	120 310 220 155 Filing a brief in support of an appeal				
114 150 214 75 Provisional filing fee	121 270 221 135 Request for oral hearing				
	138 1,510 138 1,510 Petition to institute a public use proceeding				
SUBTOTAL (1) (\$) 740.00	140 110 240 55 Petition to revive - unavoidable				
2. EXTRA CLAIM FEES	141 1,240 241 620 Petition to revive - unintentional				
Fee from Extra Claims below Fee Paid	142 1,240 242 620 Utility issue fee (or reissue)				
Total Claims 1 -20** = 0 x 18.00 = 0.00	143 440 243 220 Design issue fee				
Independent	144 600 244 300 Plant issue fee				
Multiple Dependent =	122 130 122 130 Petitions to the Commissioner				
	123 130 123 130 Petitions related to provisional applications				
Large Entity Small Entity	126 180 126 180 Submission of Information Disclosure Stmt				
Fee Fee Fee Fee Description Code (\$) Code (\$) 103 18 203 9 Claims in excess of 20	581 40 581 40 Recording each patent assignment per property (times number of properties)	\$40.00			
102 80 202 40 Independent claims in excess of 3	146 710 246 355 Filing a submission after final rejection				
104 270 204 135 Multiple dependent claim, if not paid	(37 ČFR § 1 129(a))				
109 80 209 40 ** Reissue independent claims over original patent	149 710 249 355 For each additional invention to be examined (37 CFR § 1 129(b))				
110 18 210 9 ** Reissue claims in excess of 20	179 710 279 355 Request for Continued Examination (RCE)				
and over original patent	169 900 169 900 Request for expedited examination of a design application				
SUBTOTAL (2) (\$) 0.00	Other fee (specify)				
**or number previously paid, if greater. For Reissues, see above	*Reduced by Basic Filing Fee Paid SUBTOTAL (3) (\$) 40.0	00			

SUBMITTED BY				Complete (if	applicable)
Name (PrintlType)	Margaret M. Wall	Registration No (Attorney/Agent)	33,462	Telephone	303-268-0066
Signature	Marcaret M. Wall			Date	Oct 18, 2001

WARNING: (Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO. Assistant Commissioner for Patents, Washington, DC 20231.

Express Mail No. EL652339952US Attorney Docket: NEX 01/C8



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:	GOLD et al.

SERIAL NO.: 09/ SEXAMINER:

FILED: OCTOBER 18, 2001 ART UNIT:

FOR: NUCLEIC ACID LIGANDS) CONFIRMATION NO.:

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

REQUEST TO TRANSFER PREVIOUSLY FILED SEQUENCE INFORMATION UNDER 37 C.F.R. §1.821(e)

The paper copy of the Sequence Listing in the instant application is identical to the computer readable copy of the Sequence Listing filed on February 10, 2000, in United States Patent Application Serial No. 09/502,344.

In accordance with 37 C.F.R. § 1.821(e), please use the only computer readable form filed in that application as the computer readable form for the instant application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the instant application. A paper copy of the Sequence Listing is included with the instant application.

I hereby state that the contents of the computer readable copy of the Sequence Listing filed in United States Patent Application Serial No. 09/502,344, filed on February 10, 2000, and the paper copy filed herewith are the same. 37 C.F.R. § 1.821(f).

Respectfully submitted,

Date: October 18, 2001

Margaret M. Wall, #34,962 Swanson & Bratschun, L.L.C. 1745 Shea Center Drive, Suite 330 Highlands Ranch, Colorado 80129

AND THE RESERVE OF THE PROPERTY OF THE PROPERT

(303) 268-0066

cc:

Diane Cruz

Vanessa Appleby

\\SWANSONBRATS01\COMPANY\CLIENT FOLDERS\\NEXSTAR\\NEX01\C8\TRANSFER OF SEQ LIST.DOC-CMB